Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

It's likely to experience a lot of growth. As a young and innovative company that heavily emphasizes the "tech" portion of the term "biotech," Recursion Pharmaceuticals (RXRX -3.56%) is a classic contender for being the kind of stock that can turn investors into millionaires. It has flashy technology and pioneering drug development methods. But can those really drive returns on the scale needed to make a relatively small investment grow to be worth millions? Buckle up and get ready for some calculations, be ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $8.19, demonstrating a -1.92% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.08%. Meanwhile, the Dow experienced a drop of 0.12%, and the technology-dominated Nasdaq saw an increase of 0.07%. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.56 per share and revenue of $47.44 million, indicating changes of +1.27% and +6.43%, respectively, compared ...

There's a lot to like about the company using automation and artificial intelligence to improve the new drugdiscovery process. Recursion Pharmaceuticals (RXRX 3.73%) is a start-up biotech company with an important twist. It's using automation technology and artificial intelligence (AI) to industrialize new drug discovery. Why Recursion Pharmaceuticals looks like a good investment New drug candidates discovered by Recursion should also have a better chance at success in clinical trials because there's a lot ...

Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (RXRX 8.85%) is aiming to position itself at the intersection of both big trends. While it isn't the only biotech exploring these rising opportunities, it just might be one of the few to have what's needed to succeed in such a dynamic time. The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly ove ...

Core Viewpoint - Recursion Pharmaceuticals is positioned at the forefront of a potential paradigm shift in drug discovery through its AI-driven approach, but it faces significant challenges and competition that may hinder its success [2][3][5]. Company Overview - Recursion Pharmaceuticals utilizes an AI algorithm to test clinical compounds against a library of human genes, aiming to enhance the probability of success from pre-clinical testing to regulatory approval [3]. - The company currently has no products on the market or in late-stage studies, which raises concerns about its approach and increases the risk associated with its stock [4][5]. Competitive Landscape - The biotech industry is witnessing increased competition, particularly from established players like Novo Nordisk, which is developing an AI supercomputer to enhance drug research and development [8][13]. - Novo Nordisk's extensive data from its drug development history and greater financial resources present a formidable challenge to Recursion Pharmaceuticals [8][14]. Development Challenges - The drug development process is inherently difficult, with many candidates failing at various stages, including pre-clinical and multiple phases of human trials [10]. - Recursion Pharmaceuticals has approximately six programs in clinical trials, most of which are in phase 2, which is not particularly impressive for a clinical-stage biotech [12]. Future Potential - If Recursion Pharmaceuticals can successfully navigate the competitive landscape and demonstrate tangible results from its AI-driven platform, it could see substantial upside potential in its stock [11][15]. - The company may benefit from a network effect as its AI algorithm learns from successes and failures, although there is currently no data to support this development [15].

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. About Recursion Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public offering of 30,769,230 shares of its Class A common stock at a pric ...

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. About Recursion Forward-Looking Statements Investor Contact: media@recursion.com Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the pricing of its underwritten public of ...

Goldman Sachs & Co. LLC and J.P. Morgan are acting as lead book-running managers for the offering. Allen & Company LLC is acting as book-running manager for the offering. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San Francisco Bay Area, and London. Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ:RXRX), a leading ...